Market News AIOpen the app

Corcept Therapeutics shared a case report showing how well relacorilant worked for a patient with metastatic vulvar cancer.

TrialRead the original at fidelity.com
Good for CORT

A published case describes a response lasting more than 105 months, longer than the patient's earlier taxane treatment. This supports relacorilant's potential, but one patient's result may not apply to others.

CORT · Corcept Therapeutics

AI read · Good for CORT

The AI's read

That case adds evidence about relacorilant's possible use in a rare cancer. The patient's disease remained stable, with no new lesions, as of July 2026. Still, one patient's experience cannot show whether other patients will respond.

Get alerts for CORT

Follow Corcept Therapeutics (CORT) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CORT
Free on the App Store and Google Play, or on the web.